Inmagene is a global clinical-stage biotechnology company focused on developing novel therapeutics for immunology-related diseases. Inmagene’s most advanced drug candidate is IMG-020 (izokibep), which has successfully met the protocol endpoints in global phase II studies for both psoriasis and psoriatic arthritis (PsA). It has received the IND approval from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) for phase III studies in plaque psoriasis. Inmagene is working with its partners to conduct global phase II studies for multiple autoimmune diseases, including PsA, ankylosing spondylitis (AS) and uveitis. In addition, IMG-004 and IMG-007, both of which with global rights, are in global phase I studies. IMG-008, an internally discovered drug candidate, is planned to submit global IND in 2022. Believing in "Borderless Innovation", the Inmagene team strives to integrate efficient resources worldwide to develop novel therapeutics for global patients. Based on its proprietary QuadraTek® drug discovery platform, Inmagene is operating "Smart Innovation" programs to create and develop drug candidates with global rights. Inmagene also in-licenses drug candidates and, together with its partners, carries out global development activities, including global multi-center clinical trials. Inmagene has formed strategic partnerships with multiple partners, such as HUTCHMED and Affibody AB, to develop highly innovative drug candidates. Inmagene has a seasoned management team. Prior to joining Inmagene, they had achieved the following accomplishments: - Played critical roles in the founding of Zai Lab (NASDAQ: ZLAB), I-Mab (NASDAQ: IMAB) and Apollomics - Led the drug development for over 20 successful NDAs - In-licensed over 30 global products for China - Obtained market approvals in 28 countries - Pushed 6 drug candidates from discovery to human trials in both China and the United States